WBCPC brings the patient perspective on AI to the European Cancer Summit 2026
The World Bladder Cancer Patient Coalition (WBCPC) is in Brussels for the European Cancer Summit 2026, organised by the European Cancer Organisation (ECO).
On November 18, 2026, our Executive Director Alex Filicevas spoke in the session “Digital Cancer Innovation for Better Care and a Stronger Europe”, alongside Tomislav Sokol MEP (European Parliament), Professor Johan Hartman (Karolinska Institutet), Professor Rozemarijn Vliegenthart (University Medical Center Groningen), Professor Regina Beets-Tan (Maastricht University) and David Dellamonica (AstraZeneca). The session was moderated by Annemiek Snoeckx and Robbe Saesen of ECO’s Digital Health Network.
The bias did not start with AI
Alex opened with findings from our global patient and carer survey. Women with bladder cancer were almost twice as likely as men to be told their symptoms were a urinary tract infection (39% compared with 21%). That means months lost, when early diagnosis means survival of up to 90%.
The bias did not arrive with AI, he said. It is already in our health records, and AI learns from those records. Three things will decide whether AI helps patients: trust, equity and partnership.
Trust, equity and partnership
Trust: In a study of 13,806 hospital patients in 43 countries, nearly three in four preferred doctors to make the final decision. In a European Patients’ Forum survey, 93% said patients should be told about AI at the start of their visit. Patients welcome AI as a helping hand, but they want a named clinician accountable and their data protected. As EU digital rules are simplified, Alex urged policymakers to cut the paperwork, not the protections.
Equity: AI can bring expert opinion to hospitals that lack it, but it can also widen gaps. A study in Nature Medicine found that AI tools reading chest X-rays missed disease more often in women and in people from lower-income backgrounds. Older people, people in Central and Eastern Europe and people who are not online risk being left out of the data. As Alex put it, if you are not in the data, AI does not see you.
Partnership: Patients must be involved by design, not by exception. That means a say in which problems AI should solve, a seat in governance bodies such as those of the European Health Data Space (EHDS), and a role in evaluating how tools work in practice.
What happens next
Asked for one policy priority for 2027, Alex called for patient involvement in AI governance to be guaranteed and resourced, from EHDS committees to hospitals, so that it becomes operational, not aspirational. We will keep pressing for this through our work, including BCLEAR, our EU co-funded health literacy project, and our second global patient survey, expected to launch in early 2027.
«“Patients are not asking Europe to slow down. We are asking Europe to bring us with it. If AI helps us find bladder cancer earlier, any cancer earlier, for everyone, women included, that is the prize.”
Alex Filicevas, Executive Director, World Bladder Cancer Patient Coalition
If you want to learn more about how BCLEAR supports health literacy and shared decision-making, please visit: https://patients.uroweb.org/bclear. You can also read our global survey paper, “Patient and Carer Experiences with Bladder Cancer: Results from a Global Survey in 45 Countries“, and explore the full report and our call to action on our survey page.



